The themes Agilent Technologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Les parts du chiffre d'affaires sont des estimations pour nine months ended July 31, 2026, pas des chiffres tirés d'un document officiel.
Infinity III liquid chromatography systems
Instruments that separate the substances in a liquid sample so a laboratory can identify and measure them.
8890B and 8860B gas chromatographs
Instruments that separate and measure substances that can be turned into gas, including chemicals in fuels and contaminants in food.
9500 triple-quadrupole inductively coupled plasma mass spectrometer
An instrument that measures very small amounts of metals and other elements, including in samples used in semiconductor manufacturing.
Altura liquid chromatography columns
Replaceable tubes that separate substances inside a chromatography system, including in testing of protein-based and nucleic-acid medicines.
Dako Omnis pathology systems
Automated instruments and related supplies used by clinical laboratories to stain and examine tissue samples for cancer diagnosis.
Oligonucleotide contract manufacturing
Manufacturing of short DNA- or RNA-like drug ingredients for pharmaceutical customers, from development through commercial production.
Agilent makes instruments that help laboratories identify and measure the chemicals, cells and other materials in samples. It also sells the supplies used with those instruments, maintains lab equipment, and provides software for collecting and managing test results. For drug companies, Agilent also makes ingredients used in some medicines and manufactures certain drug materials under contract.
Construit à partir des documents déposés par Agilent Technologies, Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
A · NYSE · Healthcare · Diagnostics and Research
173,02 $US-2,2 %clôture 12 nov.
Prochains résultats : 23 novembre 2026 · après la clôture
Chiffres jusqu’au 31 juillet 2026, issus du 10-Q déposé le 1 septembre 2026
Agilent sells laboratory supplies and maintenance services, plus scientific instruments, to pharmaceutical companies, hospitals, research labs and testing laboratories.
Prévision de l’entreprise : chiffre d’affaires de de 7,5B $US à 7,5B $US pour Exercice 2026 — en hausse de 7,9 % sur un an
Grade B+
La bande sous le cours montre la note à chaque date, établie uniquement à partir des documents publics à ce moment-là.
Affichage de 2 trimestres sur 40 de l’historique des notes de Agilent Technologies, Inc.. Les 38 autres remontent jusqu’à décembre 2016.